Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study.

Artemisinin resistance in Plasmodium falciparum threatens to reduce the efficacy of artemisinin combination therapies (ACTs), thus compromising global efforts to eliminate malaria. Recent treatment failures with dihydroartemisinin-piperaquine, the current first-line ACT in Cambodia, suggest that pip...

Full description

Bibliographic Details
Main Authors:	Amaratunga, C, Lim, P, Suon, S, Sreng, S, Mao, S, Sopha, C, Sam, B, Dek, D, Try, V, Amato, R, Blessborn, D, Song, L, Tullo, G, Fay, M, Anderson, J, Tarning, J, Fairhurst, R
Format:	Journal article
Language:	English
Published:	Lancet 2016

Dihydroartemisinin–piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study by Amaratunga, C, Lim, P, Suon, S, Sreng, S, Mao, S, Sopha, C, Sam, B, Dek, D, Try, V, Amato, R, Blessborn, D, Song, L, Tullo, G, Fay, M, Anderson, J, Tarning, J, Fairhurst, R

Published 2016

Journal article

Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study.

Similar Items